(NRIFF) Price: 0.065 // 3 Approved drugs + FDA decision on March 4 = 10 BAGGER RALLYYYYYYYYYYYYYYYYYYYYYYYYYYY
You can buy this undiscovered BIG Goldmine currently at almost all time low .This is what is called a once in a lifetime opportunity .GLTA
FDA approval for Pennsaid (A Best in Class topical medication for osteoarthritis) on March 4 ,2013 . Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for U.S., targeting $8B oral NSAID market
Nuvo will hit profitability this year with 2 new product launches in 2Q 2013 .Annual Revenue already hits $30 M .Nasdaq Listing is planned for this year which will bring more attention to this Goldmine .
A REAL 10 BAGGER HERE ...GLTA
Nuvo Research (NRI.TO) or (NRIFF)
Marktkap : $ 36 M
Cash: $ 12 M
Kurs: 0.065 $
Growing revenue with 3 approved pain products:
Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
U.S., targeting $8B oral NSAID market
Pliaglis®: analgesic peelable cream, targeting global cosmetic and
dermatology markets, partnered with Galderma, worldwide launch
commencing Q2 2013
PropThink: Nuvo Research Gaining visibility; New Patent for Pennsaid 2% is Positive
Nuvo Research Inc. (TSX:NRI) announced that it obtained an additional U.S. patent for Pennsaid 2%, an improved follow-on formulation of its currently marketed Pennsaid product. Pennsaid contains the anti-inflammatory drug diclofenac, which is applied on the skin for pain conditions such as osteoarthritis of the knee. Pennsaid is currently marketed by Covidien's (NYSE:COV) pharmaceutical division Mallinkrodt, and Pennsaid 2% is undergoing FDA review for approval. The new version is a higher strength version of the product, and is formulated to increase the penetration of diclofenac through the skin to the site of pain. Importantly, the new formulation, if approved, will have patent protection out to 2028, and could become an important product for Covidien's pharmaceutical division, which is expected to be spun out to COV shareholders as a pure-play company in mid-2013. In July, Nuvo and Covidien announced that the FDA had accepted their New Drug Application (NDA) for Pennsaid 2% with a PDUFA (FDA action) date of March 4, 2013. Covidien stated that once Pennsaid 2% is approved, it expects to have the new patent listed in the FDA's Orange Book.
NRI shares remain on the radar screen, but could gain visibility on its portfolio of products for the topical treatment of pain. In addition to Covidien, the company is partnered with leading dermatology company Galderma, which is gearing up for approval and launch of Pliaglis. Pliaglis is Nuvo's topical anesthetic cream that will be marketed by Galderma for the reduction of pain associated with dermatological procedures. Several European countries have already notified Galderma that Pliaglis has been approved, and Galderma has responded to a Complete Response Letter (CRL) in the U.S. for potential FDA approval. Nuvo is also re-launching its Synera product, a topical anesthetic patch approved in the U.S. to provide pain relief for superficial dermatological procedures, and the company may seek to partner the drug in major markets. With only a $36 million market cap, shares of Nuvo Research have substantial room to run as U.S. investors become more familiar with the company.